Tuesday, October 07, 2025 3:37:30 PM
Investor082,
Nope, IFRs are not last resort they are first step for those seeking treatment of an approved but not yet reimbursed medicine under a NICE agreement. Hence a heavy load will shift to the five doctor panel considering IFR requests for treatment with murcidencel under a cancer, not GBM, designation on NHS’s high priced medicines list. No excuses by them and NHS for not being ready right?; ).
I know this seems to escape you but Doctors will do what their patients need done and that includes the paperwork needed for submitting an IFR. The funding for IFRs has increased significantly over the last year and because of the the broad nature of the indication on the high priced medicines list many types of cancer will be treated which is an obvious now to RWD from Specials. Go look up funding amounts shared on this board over the last year or so and feel free to share; ). Best wishes.
Nope, IFRs are not last resort they are first step for those seeking treatment of an approved but not yet reimbursed medicine under a NICE agreement. Hence a heavy load will shift to the five doctor panel considering IFR requests for treatment with murcidencel under a cancer, not GBM, designation on NHS’s high priced medicines list. No excuses by them and NHS for not being ready right?; ).
I know this seems to escape you but Doctors will do what their patients need done and that includes the paperwork needed for submitting an IFR. The funding for IFRs has increased significantly over the last year and because of the the broad nature of the indication on the high priced medicines list many types of cancer will be treated which is an obvious now to RWD from Specials. Go look up funding amounts shared on this board over the last year or so and feel free to share; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
